Oncolytics biotech incorporated ONCY.US Overview Analysis

US StockHealth Care
(No presentation for ONCY)

ONCY AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.

ONCY Current Performance

4.03%

Oncolytics biotech incorporated

1.31%

Avg of Sector

0.58%

S&P500

Top 10 High Relevance to ONCY

  • MBX Mbx biosciences inc
    Value -Trend 3Swing Trading 4Whale Interest 2Dividend 1
    See more

ONCY Profile

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company's primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Price of ONCY